JP2019516756A - 非統合失調症患者の陰性症状を治療するための方法および組成物 - Google Patents

非統合失調症患者の陰性症状を治療するための方法および組成物 Download PDF

Info

Publication number
JP2019516756A
JP2019516756A JP2018561528A JP2018561528A JP2019516756A JP 2019516756 A JP2019516756 A JP 2019516756A JP 2018561528 A JP2018561528 A JP 2018561528A JP 2018561528 A JP2018561528 A JP 2018561528A JP 2019516756 A JP2019516756 A JP 2019516756A
Authority
JP
Japan
Prior art keywords
patient
compound
weeks
patients
severe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018561528A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019516756A5 (https=
Inventor
レミ・リュトランジェ
マイケル・デイビッドソン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of JP2019516756A publication Critical patent/JP2019516756A/ja
Publication of JP2019516756A5 publication Critical patent/JP2019516756A5/ja
Priority to JP2022160201A priority Critical patent/JP2022188185A/ja
Priority to JP2024173054A priority patent/JP2025000921A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2018561528A 2016-05-25 2017-05-23 非統合失調症患者の陰性症状を治療するための方法および組成物 Pending JP2019516756A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022160201A JP2022188185A (ja) 2016-05-25 2022-10-04 非統合失調症患者の陰性症状を治療するための方法および組成物
JP2024173054A JP2025000921A (ja) 2016-05-25 2024-10-02 非統合失調症患者の陰性症状を治療するための方法および組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662341590P 2016-05-25 2016-05-25
US62/341,590 2016-05-25
PCT/US2017/034030 WO2017205393A1 (en) 2016-05-25 2017-05-23 Compositions and methods for treating negative symptoms in non-schizophrenic patients

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022160201A Division JP2022188185A (ja) 2016-05-25 2022-10-04 非統合失調症患者の陰性症状を治療するための方法および組成物

Publications (2)

Publication Number Publication Date
JP2019516756A true JP2019516756A (ja) 2019-06-20
JP2019516756A5 JP2019516756A5 (https=) 2020-07-02

Family

ID=58794265

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018561528A Pending JP2019516756A (ja) 2016-05-25 2017-05-23 非統合失調症患者の陰性症状を治療するための方法および組成物
JP2022160201A Pending JP2022188185A (ja) 2016-05-25 2022-10-04 非統合失調症患者の陰性症状を治療するための方法および組成物
JP2024173054A Withdrawn JP2025000921A (ja) 2016-05-25 2024-10-02 非統合失調症患者の陰性症状を治療するための方法および組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022160201A Pending JP2022188185A (ja) 2016-05-25 2022-10-04 非統合失調症患者の陰性症状を治療するための方法および組成物
JP2024173054A Withdrawn JP2025000921A (ja) 2016-05-25 2024-10-02 非統合失調症患者の陰性症状を治療するための方法および組成物

Country Status (9)

Country Link
US (2) US20190216793A1 (https=)
EP (1) EP3463356A1 (https=)
JP (3) JP2019516756A (https=)
KR (2) KR20240005110A (https=)
CN (3) CN109689055A (https=)
PH (1) PH12018502445A1 (https=)
SG (2) SG11201810358YA (https=)
TW (2) TWI820001B (https=)
WO (1) WO2017205393A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2910528T3 (es) 2014-12-02 2022-05-12 Minerva Neurosciences Inc Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil)piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia
IL308650B2 (en) 2017-06-21 2025-08-01 Minerva Neurosciences Inc Gastro-resistant controlled release oral dosage forms
KR102886241B1 (ko) * 2018-08-21 2025-11-14 미쓰비시 타나베 파마 코퍼레이션 음성 증상 및 장애를 치료하고, 신경가소성을 증가시키고, 신경보호를 촉진시키기 위한 롤루페리돈의 용도
TWI879755B (zh) * 2020-02-20 2025-04-11 日商田邊三菱製藥股份有限公司 魯哌啶酮用於治療負性症狀及疾病、增加神經可塑性及促進神經保護的用途
KR102360137B1 (ko) * 2020-03-25 2022-02-08 주식회사 케이티앤지 카트리지 및 이를 포함하는 에어로졸 생성 장치
IL304920A (en) * 2021-02-09 2023-10-01 Xenon Pharmaceuticals Inc A voltage-gated potassium channel opener for use in the treatment of anhedonia
US20240212824A1 (en) * 2022-12-21 2024-06-27 Woebot Labs, Inc. Administering a digital therapeutic using a device interface to treat anxiety or depression

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4859324B2 (ja) * 2000-02-29 2012-01-25 田辺三菱製薬株式会社 新規環状アミド誘導体
JP2013531072A (ja) * 2010-07-20 2013-08-01 キレナイク・ファーマシューティカルズ，インコーポレーテッド 統合失調症を処置するための環状アミド誘導体の使用の方法
JP2013531073A (ja) * 2010-07-20 2013-08-01 キレナイク・ファーマシューティカルズ，インコーポレーテッド シグマ受容体に仲介される障害を処置するための環状アミド誘導体の使用の方法
JP2015522075A (ja) * 2012-07-12 2015-08-03 ダニエル・シー・ジャヴィット ヒトにおけるうつ病及び精神病の治療のための組成物及び方法
WO2015174534A1 (ja) * 2014-05-16 2015-11-19 武田薬品工業株式会社 含窒素複素環化合物
WO2016089766A1 (en) * 2014-12-02 2016-06-09 Minerva Neurosciences, Inc. Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200616608A (en) * 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
US20090088449A1 (en) * 2006-02-07 2009-04-02 Mitsubishi Tanabe Pharma Corporation 4-acylaminopyridine derivative mediated neurogenesis
KR20080089279A (ko) * 2007-03-30 2008-10-06 미쓰비시 타나베 파마 코퍼레이션 우울증의 예방 및/또는 치료제
US8937900B2 (en) * 2010-07-20 2015-01-20 Qualcomm Incorporated Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4859324B2 (ja) * 2000-02-29 2012-01-25 田辺三菱製薬株式会社 新規環状アミド誘導体
JP2013531072A (ja) * 2010-07-20 2013-08-01 キレナイク・ファーマシューティカルズ，インコーポレーテッド 統合失調症を処置するための環状アミド誘導体の使用の方法
JP2013531073A (ja) * 2010-07-20 2013-08-01 キレナイク・ファーマシューティカルズ，インコーポレーテッド シグマ受容体に仲介される障害を処置するための環状アミド誘導体の使用の方法
JP2015522075A (ja) * 2012-07-12 2015-08-03 ダニエル・シー・ジャヴィット ヒトにおけるうつ病及び精神病の治療のための組成物及び方法
WO2015174534A1 (ja) * 2014-05-16 2015-11-19 武田薬品工業株式会社 含窒素複素環化合物
WO2016089766A1 (en) * 2014-12-02 2016-06-09 Minerva Neurosciences, Inc. Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WINOGRAD-GURVICH C: "NEGATIVE SYMPTOMS: A REVIEW OF SCHIZOPHRENIA, MELANCHOLIC DEPRESSION AND PARKINSON'S DISEASE", BRAIN RESEARCH BULLETIN, vol. VOL:70, NR:4-6,, JPN6021019067, 16 October 2006 (2006-10-16), GB, pages 312 - 321, ISSN: 0004695749 *

Also Published As

Publication number Publication date
US20230190726A1 (en) 2023-06-22
TWI851224B (zh) 2024-08-01
PH12018502445A1 (en) 2019-09-09
WO2017205393A1 (en) 2017-11-30
CN113908156A (zh) 2022-01-11
TWI820001B (zh) 2023-11-01
CN109689055A (zh) 2019-04-26
TW202335672A (zh) 2023-09-16
KR20190013846A (ko) 2019-02-11
US20190216793A1 (en) 2019-07-18
SG11201810358YA (en) 2018-12-28
JP2022188185A (ja) 2022-12-20
SG10202011470UA (en) 2021-01-28
JP2025000921A (ja) 2025-01-07
TW201808288A (zh) 2018-03-16
CN113694065A (zh) 2021-11-26
EP3463356A1 (en) 2019-04-10
KR20240005110A (ko) 2024-01-11

Similar Documents

Publication Publication Date Title
JP2019516756A (ja) 非統合失調症患者の陰性症状を治療するための方法および組成物
US20230023092A1 (en) Treatment of depression and other various disorders with psilocybin
Adie PART 3, VOL. 49. IDIOPATHIC NARCOLEPSY: A DISEASE SUI GENERIS; WITH REMARKS ON THE MECHANISM OF SLEEP.
Vallar Spatial neglect, Balint-Homes' and Gerstmann's syndrome, and other spatial disorders
US20060252761A1 (en) Augmentation of extinction via administration of sub-antimicrobial doses of D-cycloserine
KR20240110816A (ko) 실로사이빈을 이용한 치료 저항성 우울증의 치료
JP2025510914A (ja) 産後うつ病の治療
KR20240122455A (ko) 치료-저항성 우울증의 치료에서 사용하기 위한 실로사이빈 및 보조적 세로토닌 재흡수 저해제
TW202310825A (zh) 減少ｎｍｄａ受體拮抗劑之副作用
Shere Group therapy with the very old
MACKLIN et al. PSYCHOTIC REACTIONS IN PROBLEM DRINKERS TREATED W! TH DISULFIRAM (ANTABUSE®)
WO2022130136A1 (en) Use of mglur5 antagonists for treating gambling disorder
WO2026068950A1 (en) Pharmaceutical compositions of 5-meo-dmt for use in the treatment of alcohol use disorders
Hoffer Natural history and treatment of thirteen pairs of identical twins, schizophrenic and schizophrenic-spectrum conditions
Bhattacharya 25 Teenage and Adolescent
Jenkins Mental health of people at work
KR20250005172A (ko) 정신 장애의 치료
Hoblyn et al. Psychiatry
Becker Put your patient to sleep: useful nondrug strategies for chronic insomnia
HK40128287A (zh) 使用ulotaront转换神经精神病学药物的方法
Strelnikova et al. Psychiatry and narcology (Part 2): workbook
Attenborough Alcohol and mood disorders
Khan Tell yourself you can handle it.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200522

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200522

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210525

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210707

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220318

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220705